Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer.
The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis.
The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures.
The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis.
The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures.
Location: United States, Massachusetts, Waltham
Employees: 11-50
Total raised: $147.6M
Founded date: 2016
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.09.2020 | Series B | $100M | - |
| 04.10.2017 | Series A | $47.6M | - |
Mentions in press and media 12
| Date | Title | Description |
| 16.04.2025 | Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights | SHANGHAI, April 16, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day under the theme of "Collaborate to Create". Senior executives from Henlius gathered with leading experts, scholars, and heads of innovatio... |
| 28.06.2022 | Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies | Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed - Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retain... |
| 04.12.2020 | GSK vet Antony Blanc signs on to become CureVac's CBO and CCO; Chris Cabell out, Paul Streck in as Arena Pharmaceuticals CMO | Antony Blanc → Enthused about the Phase I data for their Covid-19 mRNA vaccine and believing they’ve cracked the cold-storage code in delivering them, CureVac has brought Antony Blanc into the fray as CBO and chief commercial ... |
| 17.09.2020 | Jim Broderick reels in a $100M Series B to explore a 'new and big' angle of immune regulation | When Jim Broderick launched Massachusetts-based Palleon Pharmaceuticals in 2015, he had an office in Cambridge’s Kendall Square, a bit of seed money, and a blank canvas. He set out to innovate within a new space in immunol... |
| 17.09.2020 | Palleon Pharmaceuticals Raises $100M in Series B Funding | Palleon Pharmaceuticals, a Waltham, Mass.-based company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, completed a $100m Series B financing. The round was led by Matrix Capital Managemen... |
| 17.09.2020 | Palleon Pharmaceuticals Raises $100 million Series B | WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the completion of a $100 million Series B financing led... |
| 17.09.2020 | Palleon Pharmaceuticals Inks $100M Series B | WALTHAM, MA, Palleon Pharmaceuticals today announced the completion of a $100 million Series B financing. >> Click here for more funding data on Palleon Pharmaceuticals >> To export Palleon Pharmaceuticals funding data to PD... |
| 06.10.2017 | Term Sheet — Friday, October 6 | DAYS OF CHANGE Happy Friday, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop In an effort to woo drivers, Uber launched an initiative called, 180 Days of Change — a campaign that aims to make “meaningful c... |
| 04.10.2017 | Palleon Pharmaceuticals Inks $47.6M Series A | WALTHAM, MA, Company focused on developing the first Glycoimmune Checkpoint Inhibitors to treat cancer, today announced the completion of a $47.6 million Series A. >> Click here for more funding data on Palleon Pharmaceuticals >... |
| 04.10.2017 | Palleon Pharmaceuticals Raises $47.6 Million Series A | WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company focused on developing the first Glycoimmune Checkpoint Inhibitors to treat cancer, today announced the completion of a $47.6 million Series A financing from leading biotech... |
Show more